Kevin Haas - 20 Dec 2024 Form 3 Insider Report for Vincerx Pharma, Inc. (VINC)

Role
Acting Chief Financial Officer
Signature
By: /s/ Kevin Haas
Issuer symbol
VINC
Transactions as of
20 Dec 2024
Net transactions value
$0
Form type
3
Filing time
06 Jan 2025, 16:29:47 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VINC Common Stock 42,776 20 Dec 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VINC Stock Option (right to buy) 20 Dec 2024 Common Stock 14,450 $0.5500 Direct F1
holding VINC Stock Option (right to buy) 20 Dec 2024 Common Stock 19,000 $0.5500 Direct F2
holding VINC Stock Option (right to buy) 20 Dec 2024 Common Stock 19,000 $0.5500 Direct F3
holding VINC Stock Option (right to buy) 20 Dec 2024 Common Stock 27,000 $0.5500 Direct F4
holding VINC Stock Option (right to buy) 20 Dec 2024 Common Stock 37,125 $0.5500 Direct F5
holding VINC Stock Option (right to buy) 20 Dec 2024 Common Stock 27,875 $0.5500 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third (1/3) vests on February 14, 2023, with the remainder vesting in twenty-four equal monthly installments thereafter.
F2 Option vests in twenty-four equal monthly installments starting from August 25, 2022.
F3 Option vests in twenty-four equal monthly installments starting from November 15, 2022.
F4 Option vests in twenty-four equal monthly installments starting from February 15, 2023.
F5 One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney